Skip to contentA
Arcutis Biotherapeutics, Inc.
A
ARQTArcutis Biotherapeutics, Inc. Q2 2024 · 10-Q
Revenue$30.86M$30.86M+494.6% vs Q2 2023 Net Income-$52.33M-$52.33MN/M vs Q2 2023 EPS Diluted-$0.42-$0.42N/M vs Q2 2023 Operating Income-$50,077,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Arcutis Biotherapeutics, Inc. · CIK 1787306 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$45,119,000N/M Margins · derivedOperating margin-162.3%+1124.1 pt vs Q2 2023
Net margin-169.6%+1198.3 pt vs Q2 2023
ended Jun 30, 2024 · filed Aug 14, 2024 · 45 d after period end